Capecitabine can induce coronary vasospasm mimicking acute coronary syndrome, highlighting the need for caution and awareness of this iatrogenic cause in patients receiving this chemotherapy.
Raises awareness for capecitabine-induced vasospasm in cancer patients with chest pain; hypothesis-generating case leaves open incidence and management strategies.
Background: Coronary heart disease with acute coronary syndrome (ACS; type II myocardial infarction) may be an iatrogenic and a reversible cause with complete recovery after cessation of the accused agent. Case Presentation: We present the case of a 52-year-old male patient who had received adjuvant chemotherapy consisting of capecitabine, 3 mg orally once per day, after resection of moderately differentiated invasive adenocarcinoma in the transverse colon. Three days (3 doses) after the initiation of chemotherapy, the patient reported typical anginal chest pain and an electrocardiogram (ECG) indicated ST-segment elevation. A repeated ECG in the catheterization laboratory showed normal results. Echocardiography showed that left ventricular systolic function was moderately to severely reduced. Coronary angiography revealed normal coronary arteries. Conclusion: Capecitabine should be used with caution, as patients receiving this medication might present with symptoms suggestive of ACS that might not always originate from epicardial coronary artery disease. There is always a possibility of vasospasm when a patient is receiving Capecitabine.
No takes yet. Share an insight, caveat, or question.
Shaer et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: